Insider trade

Akari Therapeutics (AKTX): CEO bought ~$9.4K

Abizer Gaslightwala, CEO at Akari Therapeutics, bought ~$9.4K of Akari Therapeutics shares.

~$9.4K
Approx. value · 10K sh @ $0.94
288K
Holds after · shares reported
Traded
Aug 21, 2025
Filed
Aug 29, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 20, 2025InsiderCEO purchased ~$12K of AKTX shares in the open market
  2. Jun 23, 2025InsiderCEO purchased ~$1.1K of AKTX shares in the open market
  3. Jun 24, 2025InsiderCEO purchased ~$6K of AKTX shares in the open market
  4. Aug 21, 2025 · this disclosureInsiderCEO purchased ~$9.4K of AKTX shares in the open market

What came next

  1. Aug 22, 2025InsiderCEO purchased ~$7.4K of AKTX shares in the open market
  2. Aug 25, 2025InsiderCEO purchased ~$2.7K of AKTX shares in the open market
  3. Sep 19, 2025Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
  4. Oct 14, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
  5. Oct 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 22, 2025, the board of directors (the “Board”) of Akari Therapeutics, plc (the “Company”), appointed Kameel Farag to serve as the Company’s interim Chief Financial Officer, effective immediately.”
  6. Nov 24, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On November 24, 2025, Akari Therapeutics, Plc (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.”
  7. Dec 16, 2025Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 2 more items)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Akari Therapeutics

For Akari Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AKTX page.

Other recent filings by Abizer Gaslightwala, CEO

The full history of Abizer Gaslightwala, CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Akari Therapeutics (AKTX) insider traded, and how much?

Abizer Gaslightwala, CEO at Akari Therapeutics, bought ~$9.4K of Akari Therapeutics shares. 10K shares at $0.94, open market.

When did it happen, and when was it made public?

Traded: Aug 21, 2025. Filed: Aug 29, 2025. That is 8 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Akari Therapeutics recently?

For Akari Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the AKTX page.

Does this mean AKTX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Akari Therapeutics

Everything OQRO holds on this company is on its AKTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data